Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

cyclo(RLsKDK) TFA

😃Good
Catalog No. T75998
Alias BK-1361 TFA, BK1361 TFA

Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.

cyclo(RLsKDK) TFA

cyclo(RLsKDK) TFA

😃Good
Purity: 98.54%
Catalog No. T75998Alias BK-1361 TFA, BK1361 TFA
Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
5 mg$899-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.54%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Cyclo(RLsKDK) TFA (BK-1361 TFA) is a cyclic peptide and selective ADAM8 metalloproteinase inhibitor, used in research on inflammation and cancer.
Targets&IC50
ADAM8:182 nM
In vitro
cyclo(RLsKDK) TFA promoted ADAM8 inhibition and CD23 shedding with IC50 values of 120 nM and 182 nM, respectively.
cyclo(RLsKDK) TFA (200 nM,0-12h) increased the activity of pro-ADAM8 [2].
cyclo(RLsKDK) TFA (200 nM/500 nM,12 h) promoted the growth of Panc1_ctrl and Panc1_A8 cells.
cyclo(RLsKDK) TFA(500 nM) causes ERK1/2 phosphorylation in Panc1_ctrl and Panc1_A8 cells. [1]
In vivo
cyclo(RLsKDK) TFA (10 μg/g once a week for 4 weeks) significantly reduced tumor volume in mice xenografted with Panc1_ctrl and Panc1_A8. [1]
SynonymsBK-1361 TFA, BK1361 TFA
Chemical Properties
Molecular Weight841.88
FormulaC33H58F3N11O11
SmilesCC(C)C[C@H]1C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCN=C(N)N)CCCCN)CC(=O)O)CCCCN)CO.C(=O)(C(F)(F)F)O
SequenceCyclo(Arg-Leu-{d-Ser}-Lys-Asp-Lys)
Sequence ShortCyclo(RL-{d-Ser}-KDK)
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 80 mg/mL (95.03 mM), Sonication is recommended.
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM1.1878 mL5.9391 mL11.8782 mL59.3909 mL
5 mM0.2376 mL1.1878 mL2.3756 mL11.8782 mL
10 mM0.1188 mL0.5939 mL1.1878 mL5.9391 mL
20 mM0.0594 mL0.2970 mL0.5939 mL2.9695 mL
50 mM0.0238 mL0.1188 mL0.2376 mL1.1878 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy cyclo(RLsKDK) TFA | purchase cyclo(RLsKDK) TFA | cyclo(RLsKDK) TFA cost | order cyclo(RLsKDK) TFA | cyclo(RLsKDK) TFA chemical structure | cyclo(RLsKDK) TFA in vivo | cyclo(RLsKDK) TFA in vitro | cyclo(RLsKDK) TFA formula | cyclo(RLsKDK) TFA molecular weight